Novo Nordisk (NVO) CEO Lars Fruergaard Jørgensen will step down after eight years at the helm of the Danish pharmaceutical giant responsible for the blockbuster drugs Ozempic and Wegovy, the company said Friday.Read more…
Novo Nordisk’s CEO is out after the Ozempic maker’s stock dropped 50% in a year Read More »
When treating obesity, semaglutide may be associated with a reduced fracture risk compared with sleeve gastrectomy. Medscape Medical News
Fracture Risk Lower With Semaglutide vs Sleeve Read More »
Limited effectiveness, weight regain, and high prevalence of adverse events are the three key limitations of semaglutide highlighted in a letter published in the JAMA Cardiology.
Researchers highlight the limitations and risks of semaglutide Read More »
A digital obesity clinic, Embla, is associated with 16.7% weight loss over 64 weeks, matching previous semaglutide trial results with less than half the dose. Medscape Medical News
Obesity App May Enable Weight Loss With Less Semaglutide Read More »
In SELECT, semaglutide was associated with a 41% reduction in major CV events within 6 months — ie, before weight loss or full dosing was achieved. Medscape Medical News
Semaglutide May Cut Cardiovascular Risk Before Weight Loss Read More »
Semaglutide can rapidly reduce heart attacks and other serious cardiovascular complications in adults with overweight or obesity who have pre-existing cardiovascular disease but not diabetes, according to a secondary analysis of the landmark Semaglutide and Cardiovascular Outcomes (SELECT) trial from the same international author team presented at the European Congress on Obesity (ECO25) in Malaga, Spain (11–14 May).
Semaglutide may provide early protection against heart disease in high-risk patients Read More »
A new study has found that people taking Eli Lilly’s obesity drug Zepbound lost almost 50% more weight than those using Novo Nordisk’s Wegovy.
Zepbound outperforms Wegovy in head-to-head weight loss study Read More »
Those who take tirzepatide, the drug sold as Zepbound and Mounjaro, could lose more weight than those who take semaglutide, known as Ozempic and Wegovy, according to new research.
Zepbound tops Wegovy for weight loss in study comparing the drugs Read More »
Eli Lilly’s (LLY) and Novo Nordisk’s (NVO) weight loss drugs went head-to-head in a weight loss study for the first time — and Eli Lilly’s drug came out on top.Read more…
Eli Lilly’s Zepbound beat Novo Nordisk’s Wegovy in a big weight loss drug study Read More »
